FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158207875> ?p ?o ?g. }

• W2158207875 endingPage "63" @default.
• W2158207875 startingPage "55" @default.
• W2158207875 abstract "The median age of patients diagnosed with essential thrombocythaemia (ET) is 65–70 years but the management of very elderly patients (aged >80 years) with ET has not been well characterized. This study aimed to document the treatment patterns of very elderly patients with ET in a multinational, real-world setting. EXELS (Evaluation of Xagrid Efficacy and Long-term Safety) is a phase IV observational study, designed to monitor the efficacy and safety of cytoreductive therapies in clinical practice. In total, 3,598 high-risk patients with ET were recruited from May 2005 to April 2009, in 13 European countries. Data were collected at registration and every 6 months thereafter for 5 years. This analysis was performed on a data-cut taken approximately 2 years after the last patient was registered. In total, 395 patients aged >80 years at registration into EXELS were included in the analysis; of these, 42.2 % had experienced a previous thrombohaemorrhagic event. At registration, the most frequently prescribed cytoreductive therapy for patients aged >80 years was hydroxycarbamide (HC), which accounted for 82.8 % of patients whereas anagrelide use was less frequent (8.6 %). Very elderly patients were more likely to be switched from anagrelide than from HC (47.1 vs. 17.4 %; 95 % confidence interval for difference in proportion 12.4–46.9; Chi-squared test p < 0.001). Median platelet count during treatment was ~430 × 109/L. In patients aged >80 years, the main reason for switch was intolerance/side effects (34.1 %); 0/16 patients reported treatment with anagrelide was non-efficacious compared with 8/57 (14 %) patients receiving HC, and 7/16 (43.8 %) anagrelide patients switched because of intolerance versus 18/57 (31.6 %) patients receiving HC. At least one predefined clinical event (PDE) was experienced by 27.3 % of patients aged >80 years. The most common PDEs reported in the very elderly age group were death (non-PDE related; 11.1 %), other cardiovascular symptoms (5.8 %), haematological transformation (3.8 %), congestive heart failure (3.3 %), myocardial infarction and angina (2.8 %), and thromboembolic events (6.3 %). Well-tolerated and effective cytoreductive therapy has been achieved in patients aged >80 years by following individual treatment modalities that appear in agreement with the recent European LeukemiaNet (ELN) guidelines. Registered as ClinicalTrials.gov identifier NCT00567502; Protocol No: SPD422-401." @default.
• W2158207875 created "2016-06-24" @default.
• W2158207875 creator A5002512182 @default.
• W2158207875 creator A5006360930 @default.
• W2158207875 creator A5008609620 @default.
• W2158207875 creator A5012374853 @default.
• W2158207875 creator A5019087367 @default.
• W2158207875 creator A5046827092 @default.
• W2158207875 creator A5054976477 @default.
• W2158207875 creator A5067372930 @default.
• W2158207875 date "2012-11-27" @default.
• W2158207875 modified "2023-09-25" @default.
• W2158207875 title "Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study" @default.
• W2158207875 cites W1494928676 @default.
• W2158207875 cites W1998721150 @default.
• W2158207875 cites W2017085228 @default.
• W2158207875 cites W2021434830 @default.
• W2158207875 cites W2027789412 @default.
• W2158207875 cites W2069651950 @default.
• W2158207875 cites W2087975811 @default.
• W2158207875 cites W2133633030 @default.
• W2158207875 cites W2134871294 @default.
• W2158207875 cites W2138058759 @default.
• W2158207875 cites W2156831708 @default.
• W2158207875 cites W2170556946 @default.
• W2158207875 cites W2229971338 @default.
• W2158207875 cites W2320032845 @default.
• W2158207875 cites W2332563262 @default.
• W2158207875 cites W2334781899 @default.
• W2158207875 cites W2462238653 @default.
• W2158207875 doi "https://doi.org/10.1007/s40261-012-0042-0" @default.
• W2158207875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3586170" @default.
• W2158207875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23184668" @default.
• W2158207875 hasPublicationYear "2012" @default.
• W2158207875 type Work @default.
• W2158207875 sameAs 2158207875 @default.
• W2158207875 citedByCount "15" @default.
• W2158207875 countsByYear W21582078752013 @default.
• W2158207875 countsByYear W21582078752014 @default.
• W2158207875 countsByYear W21582078752015 @default.
• W2158207875 countsByYear W21582078752016 @default.
• W2158207875 countsByYear W21582078752019 @default.
• W2158207875 countsByYear W21582078752020 @default.
• W2158207875 countsByYear W21582078752022 @default.
• W2158207875 crossrefType "journal-article" @default.
• W2158207875 hasAuthorship W2158207875A5002512182 @default.
• W2158207875 hasAuthorship W2158207875A5006360930 @default.
• W2158207875 hasAuthorship W2158207875A5008609620 @default.
• W2158207875 hasAuthorship W2158207875A5012374853 @default.
• W2158207875 hasAuthorship W2158207875A5019087367 @default.
• W2158207875 hasAuthorship W2158207875A5046827092 @default.
• W2158207875 hasAuthorship W2158207875A5054976477 @default.
• W2158207875 hasAuthorship W2158207875A5067372930 @default.
• W2158207875 hasBestOaLocation W21582078751 @default.
• W2158207875 hasConcept C126322002 @default.
• W2158207875 hasConcept C141071460 @default.
• W2158207875 hasConcept C187212893 @default.
• W2158207875 hasConcept C197934379 @default.
• W2158207875 hasConcept C23131810 @default.
• W2158207875 hasConcept C2780829020 @default.
• W2158207875 hasConcept C2781057849 @default.
• W2158207875 hasConcept C44249647 @default.
• W2158207875 hasConcept C535046627 @default.
• W2158207875 hasConcept C61943457 @default.
• W2158207875 hasConcept C71924100 @default.
• W2158207875 hasConcept C89560881 @default.
• W2158207875 hasConceptScore W2158207875C126322002 @default.
• W2158207875 hasConceptScore W2158207875C141071460 @default.
• W2158207875 hasConceptScore W2158207875C187212893 @default.
• W2158207875 hasConceptScore W2158207875C197934379 @default.
• W2158207875 hasConceptScore W2158207875C23131810 @default.
• W2158207875 hasConceptScore W2158207875C2780829020 @default.
• W2158207875 hasConceptScore W2158207875C2781057849 @default.
• W2158207875 hasConceptScore W2158207875C44249647 @default.
• W2158207875 hasConceptScore W2158207875C535046627 @default.
• W2158207875 hasConceptScore W2158207875C61943457 @default.
• W2158207875 hasConceptScore W2158207875C71924100 @default.
• W2158207875 hasConceptScore W2158207875C89560881 @default.
• W2158207875 hasIssue "1" @default.
• W2158207875 hasLocation W21582078751 @default.
• W2158207875 hasLocation W21582078752 @default.
• W2158207875 hasLocation W21582078753 @default.
• W2158207875 hasLocation W21582078754 @default.
• W2158207875 hasOpenAccess W2158207875 @default.
• W2158207875 hasPrimaryLocation W21582078751 @default.
• W2158207875 hasRelatedWork W113810927 @default.
• W2158207875 hasRelatedWork W1586374228 @default.
• W2158207875 hasRelatedWork W2003938723 @default.
• W2158207875 hasRelatedWork W2047967234 @default.
• W2158207875 hasRelatedWork W2118496982 @default.
• W2158207875 hasRelatedWork W2364998975 @default.
• W2158207875 hasRelatedWork W2369162477 @default.
• W2158207875 hasRelatedWork W2439875401 @default.
• W2158207875 hasRelatedWork W4238867864 @default.
• W2158207875 hasRelatedWork W2525756941 @default.
• W2158207875 hasVolume "33" @default.
• W2158207875 isParatext "false" @default.
• W2158207875 isRetracted "false" @default.

• next